DiaMedica Therapeutics Inc (DMAC)’s stock has witnessed a price hike of 1.99% from the previous close with its current price standing at $4.10. Its current price is -17.17% under its 52-week high of $4.95 and 91.59% more than its 52-week low of $2.14. Based on the past 30-day period, the stock price is -10.04% below the high and +2.81% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, DMAC’s SMA-200 is $3.38.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DMAC’s price to book ratio for the most recent quarter was 3.66, resulting in an 3.49 price to cash per share for the period.
How does DiaMedica Therapeutics Inc (DMAC) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 4 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 5.00 in simple terms.
DiaMedica Therapeutics Inc (DMAC): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 2 different analysts, who are expecting earnings to fall in between the range of -0.16 and -0.18 with an average Earnings Estimate of -0.17 which is in contrast with the last year earnings estimate of -0.14 and also replicates -21.43% growth rate year over year.
DiaMedica Therapeutics Inc (NASDAQ: DMAC) Ownership Details
I will give a breakdown of the key shareholders in DiaMedica Therapeutics Inc (DMAC). Recent figures show that the company’s insiders hold 26.23% of shares. A total of 54 institutional investors hold shares in the company, making 31.61% of its stock and 42.84% of its float.
Sep 30, 2024, it was reported that the Company’s largest institutional holder is Cooperman, Leon G. holding total of 1.51 shares that make 3.54% of the company’s total number of shares and are currently priced at 6.2 million.
The securities firm Vanguard Group Inc holds 1.05 shares of DMAC, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 2.45%, and the holding percentage of shares is valued at 4.3 million.
An overview of DiaMedica Therapeutics Inc’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests DiaMedica Therapeutics Inc (DMAC) traded 95,567 shares per day, with a moving average of $4.24 and price change of -0.30. With the moving average of $4.28 and a price change of -0.26, about 72,719 shares changed hands on average over the past 50 days. Finally, DMAC’s 100-day average volume is 60,413 shares, alongside a moving average of $3.94 and a price change of +1.23.
